Materials·Specialty Chemicals·$5.6B
Balchem Corp (BCPC) operates in the materials sector, focusing on specialty chemicals. The company plays a crucial role in providing innovative solutions for various industries, including food, pharmaceuticals, and agriculture, which are increasingly important as global demand for sustainable products rises.
EPS
Earnings per share is a key indicator of profitability and will show how well the company has managed costs and revenues.
Revenue
Total revenue reflects the company's ability to generate sales and is critical for assessing growth potential.
Wall Street expectations, options signals, track record, and call prep available with Pro.
EPS Beat Streak
1Q
EPS Beat Rate
75%
Avg EPS Surprise
+4.66%
Avg Stock Reaction
+1.31%
In Q4-2025, Balchem reported an EPS of $1.31, surpassing estimates by 1.95%. However, the stock fell by 2.11% the following day, indicating mixed market reactions.
Management Promises & Guidance
Analysts expect Balchem to report solid earnings this quarter, with a consensus EPS of $1.33 and revenue of $267 million. The company has a history of beating earnings estimates, which could influence investor sentiment.
Bull Case
If Balchem exceeds EPS and revenue expectations, it could signal strong operational performance and growth, leading to positive stock movement.
Bear Case
Conversely, if the company misses estimates or provides weak guidance, it could raise concerns about its growth trajectory and market position.
EPS
$1.33Earnings per share is a key indicator of profitability and will show how well the company has managed costs and revenues.
Revenue
$267MTotal revenue reflects the company's ability to generate sales and is critical for assessing growth potential.
The print will turn on these two things.
Q1
Will Balchem's EPS exceed the consensus estimate of $1.33?
A beat on EPS would reinforce the company's growth narrative and could lead to a positive stock reaction.
Q2
What guidance, if any, will management provide regarding future revenue growth?
Any forward-looking statements on revenue growth will be crucial for assessing the company's outlook and investor confidence.
Why consensus could be wrong
The consensus may underestimate Balchem's revenue potential due to its innovative product lines that cater to growing sectors like health and nutrition.
Supporting Evidence
Balchem has a strong track record of beating EPS estimates, with a 75% success rate over the last eight quarters.
The company's focus on specialty chemicals positions it well in a market that values sustainability and innovation.
Key Risk
If revenue growth significantly outpaces expectations, it could challenge the current consensus view.
Pre-commit to what would confirm each case.
This quarter's performance will hinge on Balchem's ability to meet or exceed expectations, particularly in a challenging economic environment.
Bull Confirmed If
An EPS of $1.35 or higher would confirm the bull case, indicating strong operational performance.
Bear Confirmed If
An EPS below $1.30 would support the bear case, raising concerns about the company's growth prospects.
Implied Move
±4.2%
The options market is pricing in a significant move around the earnings report, suggesting that investors are anticipating volatility.
Likely market behavior by outcome — not investment advice.
Beat & Raise
If Balchem beats expectations, history suggests the stock could rise by around 1.51%, confirming a positive outlook.
In-Line / Cautious
If results are in line with expectations, the stock may see muted movement as investors await further commentary.
Miss
Should the company miss estimates, the stock could decline by about 0.73%, reflecting investor disappointment.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
VERIZON COMMUNICATIO
Apr 27, 2026